Search

Displaying results 4181 - 4190 of 4860 in total
  1. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers.

  2. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    It was being developed by Anesiva, but trials have halted.

  3. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

  4. Drug

    Lubazodone

    go.drugbank.com/drugs/DB09196
    Experimental

    It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.

  5. Drug

    Olenasufligene relduparvovec

    go.drugbank.com/drugs/DB16264
    Investigational

    It is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.[L46671]

  6. Drug

    VTX-801

    go.drugbank.com/drugs/DB17646
    Investigational

    It is being investigated in Wilson Disease.[L45924]

  7. Drug

    RP-A501

    go.drugbank.com/drugs/DB17647
    Investigational

    It is being investigated for Danon disease.[L45934]

  8. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome

  9. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103]

  10. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation